Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
Final 2025 global cohort onboarding, with applications now open for 2026WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ...
A major observational study presented at EACVI 2025 found that valvular heart disease is common in patients with prior cancer diagnoses, with 7.2% showing severe disease on echocardiography.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results